GenSight Biologics S.A. Logo

GenSight Biologics S.A.

Developing gene therapies for neurodegenerative diseases of the eye and central nervous system.

SIGHT | PA

Overview

Corporate Details

ISIN(s):
FR0013183985 (+3 more)
LEI:
549300NK4AB8OUEX1F54
Country:
France
Address:
74 RUE DU FAUBOURG SAINT-ANTOINE, 75012 PARIS
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

GenSight Biologics S.A. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative gene therapies for retinal neurodegenerative diseases and other severe inherited diseases of the eye and central nervous system. The company leverages proprietary technology platforms, including Mitochondrial Targeting Sequence (MTS) and optogenetics, to create product candidates designed for administration as a single treatment. Its pipeline includes lenadogene nolparvovec (GS010), which is in late-stage clinical development, and GS030, currently in Phase I/II trials.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-29 21:50
Interim Report
rapport financier semestriel 2025
English 769.3 KB
2025-07-22 19:00
Capital/Financing Update
Inside Information / Operations of the issuer (acquisitions, sales...)
English 220.0 KB
2025-07-22 19:00
Share Issue/Capital Change
Informations privilégiées / Opérations de l'émetteur (acquisitions, cessions...)
French 207.1 KB
2025-07-11 11:27
Major Shareholding Notification
Franchissement de seuils
French 114.0 KB
2025-07-03 21:19
Share Issue/Capital Change
Informations privilégiées / Opérations de l'émetteur (acquisitions, cessions...)
French 247.4 KB
2025-07-03 21:19
Capital/Financing Update
Inside Information / Operations of the issuer (acquisitions, sales...)
English 243.8 KB
2025-06-26 07:30
Regulatory News Service
Inside Information / Other news releases
English 165.8 KB
2025-06-26 07:30
Regulatory News Service
Informations privilégiées / Autres communiqués
French 155.9 KB
2025-06-12 19:02
Regulatory News Service
Inside Information / Other news releases
English 207.0 KB
2025-06-12 19:02
Legal Proceedings Report
Informations privilégiées / Autres communiqués
French 176.7 KB
2025-05-13 22:00
Post-Annual General Meeting Information
Inside Information / Other news releases
English 85.1 KB
2025-05-13 22:00
Post-Annual General Meeting Information
Informations privilégiées / Autres communiqués
French 114.2 KB
2025-04-23 20:30
Pre-Annual General Meeting Information
Inside Information / Other news releases
English 82.1 KB
2025-04-23 20:30
Pre-Annual General Meeting Information
Informations privilégiées / Autres communiqués
French 113.3 KB
2025-04-08 15:55
Annual Report (ESEF)
URD 2024
English 22.4 MB

Automate Your Workflow. Get a real-time feed of all GenSight Biologics S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for GenSight Biologics S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-05-09 N/A Other Other 5,063,291 1,999,999.95 EUR
2024-02-07 N/A Other Other 5,224,660 1,999,999.85 EUR
2023-11-21 N/A Other Other 3,038,279 2,163,862.30 EUR

Peer Companies

Company Country Ticker View
1NKEMIA Logo
A tech group providing R&D, services, training, and investment for life sciences industries.
Spain IKM
AI-powered genome sequencing and reanalysis to diagnose rare diseases globally.
South Korea 394800
Develops antibody therapeutics and CAR-T for oncology and provides CRO services.
South Korea 174900
Clinical-stage biopharma developing therapeutics for oncology & viral infectious diseases.
South Korea 203400
ABL Bio Inc. Logo
Develops bispecific antibody therapies for oncology and neurodegenerative diseases.
South Korea 298380
Acticor Biotech Logo
Clinical-stage biopharma developing a first-in-class drug for thrombotic diseases like stroke.
France ALACT
Adecco Group AG Logo
Global talent solutions firm offering staffing, placement, career transition, and tech consulting.
Switzerland ADI1
ADforus Co., Ltd. Logo
Ad-tech firm with AI platforms for mobile marketing and publisher monetization solutions.
South Korea 397810
Adocia Logo
Biotech improving protein drug formulations for diabetes & obesity and developing cell therapies.
France ADOC
ad pepper media International N.V. Logo
Global performance marketing & audience targeting solutions for advertisers and agencies worldwide.
Germany APM

Talk to a Data Expert

Have a question? We'll get back to you promptly.